Determinants of failure to prescribe target doses of angiotensin-converting enzyme inhibitors for heart failure

European Journal of Heart Failure

Volumn 5, Issue 5, 2003, Pages 693-696

  Manyemba, Juliet ^a   Mangoni, Arduino A ^a   Pettingale, Keith W ^a   Jackson, Stephen H D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; NITRATE; PERINDOPRIL; RAMIPRIL; SPIRONOLACTONE;

ADULT; AGED; AORTA STENOSIS; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DRUG CONTRAINDICATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 0346730900     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(03)00055-2     Document Type: Article

References (14)

1. For the Collaborative Group on ACE Inhibitor Trials, Garg R, Yusuf S. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
2. Flather MD, Yusuf S, Pfeffer M, Hall A, Murray G. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
3. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
4. NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998;19:481-9.
5. Chen Y-T, Wang Y, Radford MJ, Krumholz HM. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. Am Heart J 2001;141:410-7.
6. Houghton AR, Cowley AJ. Why are angiotensin-converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7-10.
7. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33.
8. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991;121:951-7.
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
10. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987;316:1429-35.
11. Smith N, Psaty B, Pitt B, Garg R, Gottdiener JS, Heckbert SR. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998;158:1074-80.
12. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
13. Philbin EF. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. Clin Cardiol 1998;21:103-8.
14. Massie BM, Armstrong PW, Cleland JGF, et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure. Results from the ATLAS Trial. Arch Intern Med 2001;161:165-71.